Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C42H53NO15.ClH |
Molecular Weight | 848.329 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 13 / 13 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]1(CCC(=O)[C@H](C)O1)O[C@H]2[C@@H](O)C[C@]([H])(O[C@@H]3[C@H](C)O[C@]([H])(C[C@@H]3N(C)C)O[C@H]4C[C@](O)(CC)[C@H](C(=O)OC)C5=CC6=C(C(=O)C7=C(O)C=CC=C7C6=O)C(O)=C45)O[C@H]2C
InChI
InChIKey=KUSMIBXCRZTVML-PCCPLWKKSA-N
InChI=1S/C42H53NO15.ClH/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29;/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3;1H/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+;/m0./s1
Molecular Formula | C42H53NO15 |
Molecular Weight | 811.8679 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 13 / 13 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.druginfosys.com/Drug.aspx?drugCode=29&drugName=Aclarubicin%20(HCl)&type=8
Curator's Comment: description was created based on several sources, including:
http://www.druginfosys.com/Drug.aspx?drugCode=29&drugName=Aclarubicin%20(HCl)&type=8
Aclarubicin (INN) or aclacinomycin A is an anthracycline drug is primarily indicated in conditions like Acute non-lymphoblastic leukemia, Breast cancer, Gastric cancer, Lymphoma, Ovarian coma, Small cell lung cancer, Thyroid cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. Aclarubicin (HCl) is used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects. Aclarubicin (HCl) is administered intravenously. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094255 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23533247 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3867405 |
Primary | Unknown Approved UseUnknown |
||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
[Torsade de pointes ventricular tachycardia in a patient with acute myelocytic leukemia]. | 1991 Sep |
|
Oxidative stress involvement in chemically induced differentiation of K562 cells. | 2000 Jan 1 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Sample Use Guides
25 to 100 mg/sq.meter. Maintenance, Every 3-4 Week
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2912388
aclarubicin (ACR) blocked the human lymphocytes progression at G1 period at the concentrations of 100 and 200 ng/ml, but the number of dead cells was not increased.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:16:26 UTC 2023
by
admin
on
Fri Dec 15 15:16:26 UTC 2023
|
Record UNII |
501948RI66
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C987
Created by
admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB00285MIG
Created by
admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
|
PRIMARY | |||
|
CHEMBL502620
Created by
admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
|
PRIMARY | |||
|
75443-99-1
Created by
admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
|
PRIMARY | |||
|
DTXSID4046658
Created by
admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
|
PRIMARY | |||
|
153751
Created by
admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
|
PRIMARY | |||
|
C95830
Created by
admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
|
PRIMARY | |||
|
278-209-3
Created by
admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
|
PRIMARY | |||
|
501948RI66
Created by
admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
|
PRIMARY | |||
|
100000078812
Created by
admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
|
PRIMARY | |||
|
DBSALT001935
Created by
admin on Fri Dec 15 15:16:26 UTC 2023 , Edited by admin on Fri Dec 15 15:16:26 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |